In patients with pulmonary hypertension (PH) or with other pulmonary or cardiac diseases, the 6-minute walking test – accompanied by the Borg dyspnea score – is frequently utilised as a semi-quantitative measure of exercise capacity [1]. The 6-minute walking distance (6 MWD) also serves as primary or key secondary endpoint in numerous clinical trials assessing the efficacy of pharmacotherapies in various forms of PH [2, 3]. Furthermore, the 6MWD is among the key non-invasive measures of multi-modal risk assessment in pulmonary arterial hypertension (PAH) [4–6]. In this context, cut-off values of 440 m and 165 m have been validated to indicate low, intermediate and high mortality risk, respectively, in the 3-strata model proposed by the current ESC/ERS guidelines [1], with an additional cut-off of 320 m to discriminate between intermediate-high and intermediate-low risk in the recently introduced 4-strata approach [7, 8].

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10627309PMC
http://dx.doi.org/10.1183/13993003.01454-2022DOI Listing

Publication Analysis

Top Keywords

pulmonary hypertension
8
6-minute walking
8
impact face
4
face masks
4
masks 6-minute
4
6-minute walk
4
walk distance
4
pulmonary
4
distance pulmonary
4
hypertension patients
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!